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Essentials 
• An international collaboration provides a consensus for clinical definitions. 
• This concerns thrombotic microangiopathies and thrombotic 
thrombocytopenic purpura (TTP). 
• The consensus defines diagnosis, disease monitoring and response to 
treatment. 
• Requirements for ADAMTS-13 are given. 
 
Abstract: 
Background Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic 
syndrome (HUS) are two important acute conditions to diagnose. Thrombotic 
Microangiopathy is a broad pathophysiological process that leads to 
microangiopathic hemolytic anemia, thrombocytopenia and involves capillary and 
small vessel platelet aggregates. The most common cause being disseminated 
intravascular coagulation (DIC), which may be differentiated by abnormal 
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coagulation. Clinically, a number of conditions present with  microangiopathic 
hemolytic anemia and thrombocytopenia (MAHAT),  including cancer, infection, 
transplantation, drugs, autoimmune disease and pre-eclampsia and HELLP 
(Hemolysis, Elevated Liver enzymes, Low Platelet count) syndrome in pregnancy. 
Despite overlapping clinical presentations, TTP and HUS have distinct 
pathophysiology and treatment pathways.  Objectives: Presented is a consensus 
document from an international working group on TTP and associated TMAs 
(thrombotic microangiopathies). Methods: The international working group has 
proposed definitions and terminology based on published information and consensus 
based recommendations.  Conclusion: The consensus aims to aid clinical decisions 
but also future studies and trials, utilizing standardized definitions. It presents 
classification of the causes of TMA, and criteria for clinical response, remission and 
relapse of congenital and immune mediated TTP. 
Introduction 
The elucidation of the pathophysiology of TTP and HUS, in the past 20 years, has 
transformed our understanding of the phenotypes, genotypes and therapies for these 
life-threatening conditions. Work on standardization has been addressed [1], but this 
document aims to develop robust criteria for future clinical use, studies and trials. 
Clinical and pathophysiologic features of TTP, atypical Hemolytic Uremic Syndrome 
(aHUS) and disorders with similar presentations, their investigation and subsequent 
management vary. This consensus document aims to rationalize and standardize 
definitions.  Conditions often included in the initial differential diagnosis of TTP are 
discussed. Definitions for remission, refractory and relapsing disease are defined. 
ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13) assays are central to diagnosis and are discussed. We therefore 
also describe the minimum requirements for validation of current and future assays. 
Methods:  
 
The development of this document involved key international, primarily clinical, 
experts in TTP and related TMAs. The concept was supported by the European 
Hematology Association, scientific working group (EHA-SWG), platelet group, who 
have endorsed this collaboration. Members of the group have met at key 
international meetings, including EHA, International Society of Thrombosis and 
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Hemostasis (ISTH) and American Society of Hematology (ASH) and all versions of 
the document have been reviewed and edited by the authors. Articles were identified 
by a computer-assisted search of the literature published in English using the 
National Library of Medicine PubMed database. The authors also undertook a 
focused review of the available literature. Where there was a lack of robust evidence, 
the international working group concluded a consensus-based approach was 
preferable. The conclusions are relevant to both children and adults. 
 
Thrombotic Microangiopathy  
The term TMA is a pathological term used to describe occlusive microvascular or 
macrovascular disease, often with intraluminal thrombus formation, but is also 
defined clinically by microangiopathic hemolytic anemia and thrombocytopenia 
(MAHAT). This does not specifically define a condition; therefore further 
investigations are required to identify the underlying cause for the presentation of a 
TMA, including TTP (Figure 1).  
Pathological Features of TMAs 
A number of different pathological entities have been identified, including: 
(i) von Willebrand factor (VWF)-platelet thrombosis; seen with severe ADAMTS-13 
deficiency related to anti-ADAMTS-13 antibodies or a congenital absence of 
ADAMTS-13, the hallmark of TTP. The characteristic pathology of TTP is the 
presence of ultra large VWF multimers and VWF and platelet rich thrombi in 
arterioles and capillaries[2, 3]. Presentation with large vessel thrombosis (stroke or 
myocardial infarction) is believed to result from vascular injury caused by thrombosis 
of the vasa vasorum   
  
(ii) Fibrin-platelet thrombosis; commonly seen in disseminated intravascular 
coagulation (DIC) [4] but occasionally seen in catastrophic antiphospholipid 
syndrome (CAPS), heparin induced thrombocytopenia (HIT), and HELLP syndrome. 
 
 (iii)  Thrombotic Microangiopathy; characterized by endothelial swelling or disruption 
associated with hyalinosis or fibrinoid necrosis, usually without an inflammatory cell 
infiltrate. Chronic TMA is associated with myointimal proliferation resulting in 
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concentric rings of cells and matrix surrounding small vessels (sometimes termed 
onion skinning), which can be indistinguishable from the effects of chronic 
hypertension. Intraluminal thrombosis is frequently present, but is not required for the 
diagnosis [5]. Examples include MAHAT caused by shiga toxin, complement 
dysregulation and drugs (eg gemcitabine). 
 
(iv) Vasculopathy/vasculitis; changes involve not only endothelial cells and intima, 
may be autoimmune (e.g. lupus vasculitis [6], scleroderma renal crisis [7]) or 
infectious (e.g. Rocky Mountain spotted fever [8] , viraemia, fungemia). An 
inflammatory component may be evident. 
 
(v) Intravascular clusters of cancer cells (tumor cell embolism) may occur in patients 
with advanced cancer [9].  
Clinical features of TMAs  
Peripheral blood film features consistent with MAHA include fragmented red blood 
cells (schistocytes), polychromasia and anemia. Quantification of 
fragmentation/schistocytes is not reliably available and remains subjective. 
Laboratory evidence of hemolysis includes elevated lactate dehydrogenase (LDH), 
reticulocytosis, low/absent haptoglobin, and a negative direct antiglobulin test. 
Thrombocytopenia will be evident in the complete blood count (CBC) and on the 
blood film [10].  
 
 Thrombotic thrombocytopenic purpura (TTP) 
Definition of TTP: MAHA with moderate or severe thrombocytopenia, 
with associated organ dysfunction, including neurologic, cardiac, 
gastrointestinal and renal involvement, although oliguria or anuric renal failure 
requiring renal replacement therapy is not typically a feature [10, 11]. TTP is 
confirmed by a severe deficiency (<10%) of ADAMTS-13 activity [2, 3] 
TTP is recognized as a multi-organ process with variable clinical features. Anemia 
may not be immediately obvious. Thrombocytopenia is generally severe (platelet 
count <30 x109/L), but higher platelet numbers do not exclude the diagnosis.  
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Presentation with renal failure requiring renal replacement is not a common feature 
of TTP. However, occasionally patients with multi organ failure may develop an 
acute kidney injury requiring renal support. Congenital TTP (cTTP) patients may 
present with acute renal failure [12].   cTTP cases may previously have been 
misclassified as HUS [13] 
Acute TTP presentations may include bleeding symptoms such as bruising, 
hematuria or thrombotic symptoms associated with neurological or cardiac 
involvement. In practice, TTP is suspected in: 
• Isolated MAHAT  
• New focal neurological symptoms, seizures or myocardial infarction (MI), with 
unexplained MAHAT  
• Prior history of TTP 
  
Confirming a diagnosis of TTP:  
Current ADAMTS-13 activity assays provide levels of sensitivity <5% or 1%. 
However, for the diagnosis of TTP, ADAMTS-13 activity levels < 10% are diagnostic. 
This is to include antibody mediated cases and cTTP, including late onset cTTP. 
The diagnosis of TTP should be confirmed with ADAMTS-13 activity performed on a 
sample taken prior to initiation of therapy, specifically plasma-based.  Samples taken 
immediately following plasma therapy may give a falsely raised ADAMTS-13 activity. 
The presence of anti-ADAMTS-13 IgG antibodies may help confirm TTP in these 
situations. However, in autoimmune TTP, >75% of patients exhibit <10% ADAMTS-
13 activity immediately before the next therapeutic plasma exchange session for 
several days after starting daily exchange therapy [14].   
Assays at diagnosis should include: ADAMTS-13 activity, functional inhibitor based 
on mixing studies, and/or an anti-ADAMTS-13 IgG. This panel should correctly 
identify TTP patients in the majority of cases.  
Measurement of ADAMTS-13 at regular intervals during treatment and in remission 
(e.g. weekly during treatment, monthly, then 3 monthly during follow-up period, 
extending to 6-12 monthly) may provide data in regard to the risk of relapse and 
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persistence of subclinical disease activity [15]. ADAMTS-13 activity <10% with or 
without a detectable inhibitor is associated with a significant risk of relapse and can 
guide elective, prophylactic therapy preventing further relapse [16-18] in iTTP. 
 Congenital TTP (Upshaw-Schulman syndrome) (cTTP): persistent severe 
deficiency (<10%) of ADAMTS-13 activity, with no evidence of anti-ADAMTS-13 
autoantibodies, confirmed by molecular analysis of the ADAMTS-13 gene 
confirming a pathogenic homozygous or compound heterozygous mutational 
defect.  
Persistent ADAMTS-13 activity <10% with no detectable anti-ADAMTS-13 IgG 
antibodies (confirmed in the acute phase and in remission after treatment) suggests 
a diagnosis of cTTP, especially in the following circumstances: 
• Neonates presenting with thrombocytopenia, red cell fragmentation on blood 
film, often with hyperbilirubinemia. 
• Children/ adults if there is a familial antecedent of TTP, especially in siblings 
from consanguineous parents. 
• First TTP episode in adulthood, in particular, during pregnancy.  
The diagnosis of cTTP is confirmed following mutational analysis [19-21].  Patients 
can present in the neonatal period, childhood or adulthood, with presentations 
typically associated with a trigger, such as infection, vaccination, or dehydration [22]. 
Pregnancy may precipitate acute manifestations in women with cTTP.  Presentation 
of TTP in pregnancy, often associated with fetal loss, particularly in the 2nd trimester, 
requires exclusion of late onset cTTP [23-25].  
The diagnosis is confirmed if pathogenic ADAMTS-13 mutations are identified. 
However, many genetic variants are of unknown significance and require expression 
studies. Infusion of plasma resulting in recovery of ADAMTS-13 activity and the 
disappearance of ADAMTS-13 activity with a half life of 2-3 days, supports the 
diagnosis of cTTP [26]. 
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  Immune mediated TTP (iTTP): 
This defines acquired TTP and can be divided into those cases in which a 
precipitating cause can or cannot be confirmed. All cases require immediate therapy 
(TPE and steroids), but differentiating subgroups can help to tailor therapy.  
 Primary iTTP: This describes acquired autoimmune TTP for which there 
is no obvious underlying precipitating cause/disease, ADAMTS-13 activity 
<10% with the presence of ADAMTS-13 autoantibodies.  
Primary iTTP accounts for the majority of cases of TTP. The precipitating factor or 
trigger for primary immune TTP has not been identified, although an underlying 
genetic risk in Caucasian patients has reported the presence of HLA DQ-7, HLA 
DRB1*11 & HLA DRB3* [27] 
 Secondary iTTP: This describes acquired autoimmune TTP for which a 
defined underlying disorder or trigger can be identified including connective 
tissue disease (such as systemic lupus erythematosis (SLE)), human 
immunodeficiency virus infection, cytomegalovirus (CMV) infection and/or a 
specific precipitating factor (e.g. pregnancy, drugs). Treatment of the 
underlying disorder and/or removing the underlying precipitant may be 
required as well as standard TTP therapy. The presence of severe deficiency 
(<10%) of ADAMTS-13 activity and ADAMTS-13 autoantibodies confirms a 
diagnosis of TTP. 
Secondary causes include infectious agents such as HIV [28] , drugs, such as 
ticlodipine, quinine, simvastatin [29, 30], trimethoprim [31] , pegylated interferon [32], 
as examples.  The association is typically rare and idiosyncratic. Pregnancy or 
certain autoimmune diseases, such as SLE [33], Sjogren’s syndrome [34] and 
rheumatoid arthritis (RA) maybe associated with iTTP. Treatment of the underlying 
precipitant or stopping implicated drugs in conjunction with acute standard therapy 
(plasma exchange and immunosuppression eg steroids) may be necessary. In HIV 
associated TTP, plasma exchange is of value, in conjunction with HAART (highly 
active antiretroviral therapy) [28, 35]. Secondary iTTP constitutes only a small 
proportion of the overall cases of TTP.  
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There remain, however, a number of cases that meet the clinical criteria for TTP, but 
with ADAMTS-13 activity levels that are not severely deficient and in whom an 
alternative diagnosis cannot be determined.  In these patients treatment with plasma 
exchange, needs to be individualized and continued only if a clear clinical benefit is 
obvious. Such cases should be discussed with expert centres in TTP/HUS. 
 
 Differential diagnosis of TMA  
There are a number of conditions that have presenting features (both clinical and 
laboratory) similar to TTP. ADAMTS-13 assays are essential in their differentiation 
(Table 1). 
Hemolytic Uremic Syndrome (HUS): HUS is defined by MAHAT and renal 
injury, which is the predominant feature. Thrombocytopenia may not be as 
severe as in TTP, and anemia at presentation can be variable (Figure 1).  
Infection Associated HUS (IA- HUS), often referred to as STEC-HUS describes an 
infectious etiology associated typically with E. coli 0157:H7, that express Shiga toxin. 
The TMA presents 5-7 days after the infection with hemorrhagic colitis. E coli 0157: 
H7 is not the only subtype associated with infection associated HUS. Indeed other 
subtypes of E coli [36], Salmonella, Shigella, and Campylobacter associated HUS 
can present similarly. 
Complement Mediated HUS (CM-HUS) usually results from defective regulation of 
the alternative complement pathway [37]. CM-HUS can be triggered by infection 
(and diarrhea may be evident at presentation), vaccinations, or pregnancy. 
Heterozygous mutations may be identified, affecting complement regulators 
including complement factors H (CFH) and I (CFI), complement factor H related 
protein (CFHR1, 3 and 5), CD46 (MCP), or gain of function mutations in C3 and 
complement factor B (CFB). CM-HUS associated with anti-complement factor H 
antibodies (associated with a polymorphic deletion of CFHR1) can also occur, 
particularly in children, and is responsive to immunosuppressive therapy [38]. CM-
HUS is also described associated with defects in other genes, including THBD, 
which encodes thrombomodulin and with bi-allelic mutation of the DGKE gene that 
encodes diacycl glycerol kinase ε, which regulates diacyl glycerol activated Protein 
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Kinase C signaling in endothelial cells. While the pathophysiology of DGKE-
associated HUS is not completely understood it is not thought to directly involve 
disruption of complement alternative pathway regulation [39]. 
Mutational analysis may take weeks to be completed and in 40-50% of cases no 
mutations are identified [40].  Therefore, treatment decisions must be made on the 
basis of the clinical presentation and absence of severe ADAMTS-13 deficiency. 
CM-HUS may respond to plasma exchange but eculizumab, a humanized 
monoclonal antibody, which binds to and inhibit C5, is more efficacious, except in 
DGKE-associated disease [41]. In addition, new complement inhibitors are being 
developed.  A C5 polymorphism, described in the Japanese population, is 
associated with a reduced response to eculizumab [42].  
 
The clinical presentation of CM-HUS can be variable and includes: 
• renal failure, MAHAT;  
• renal failure with MAHA but a normal platelet count;  
• chronic or progressive renal failure, without a history of MAHA;  
• severe hypertension, MAHA or thrombocytopenia, with or without renal 
impairment, often diagnosed by renal biopsy. 
In addition to molecular testing, a response to anti-complement therapy may provide 
confirmation of the diagnosis.  
Rare secondary causes have been identified causing HUS [43](Table 1).  
 
Definition of hematological response to treatment 
Clinical Response: Sustained normalization of platelet counts above the lower 
limit of the established reference range (eg >150x109/L) and LDH (<1.5 upper 
limit of normal (ULN)) after cessation of plasma exchange. 
Clinical Remission:  Clinical response after cessation of plasma exchange and 
maintained for greater than 30 days. 
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Clinical response and clinical remission would be associated with stabilization of 
parameters if end organ damage is severe or improvement in function with 
normalization of laboratory parameters.  
Exacerbation: reduction in platelet count to below the lower limit of the 
established reference range (eg<150 x 109/L), increased LDH, and the need to 
restart plasma exchange within 30 days of the last  plasma exchange after a 
clinical response to plasma exchange. 
Relapse: Fall in platelet count to below the lower limit of the established 
reference range (eg <150 x 10^9/L), +/- clinical symptoms >30 days after 
stopping plasma exchange for an acute TTP episode, requiring re-initiation of 
therapy. This is usually associated with a new increase in LDH. 
In patients achieving a normal platelet count, a >10% reduction within 24 hours may 
represent impending exacerbation (during a period of daily plasma exchange therapy 
or within 30 days of stopping plasma exchange) or relapse and requires close 
monitoring.  Exacerbation or relapse may not demonstrate the full spectrum of  
clinical features seen in the initial acute TTP presentation. ADAMTS-13 activity will 
be  <10% at exacerbation/relapse, either as a persisting deficiency or a de novo 
deficiency after transient normalisation.  
Refractory TTP:  Persistent thrombocytopenia, lack of sustained platelet count 
increment or platelet counts <50 x109/L and persistently raised LDH (>1.5 X 
ULN) despite 5  plasma exchange [44] and steroid treatment.  This would be 
defined as SEVERE if the platelet count remained < 30 x 109/L. 
Normalization of a platelet count is typically above the lower limit of the established 
reference range (eg >150x109/L), however, country/regional variability relating to the 
‘normal range’ should be noted. LDH may not be in the normal laboratory range with 
clinical response or remission, but decreasing levels with increasing platelet counts 
is in keeping with clinical response. 
The definition of refractory TTP can be challenging. Cases with an initial response, 
but then a reduced platelet count that is difficult to increase, may be considered 
refractory and this may occur after 5  plasma exchange procedures. However, the 
clinical condition is likely to be more stable at this point. 
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Intensive plasma exchange refers to increased volumes per plasma exchange eg a 
single volume to 1.5 plasma volume or increased frequency of plasma exchange eg 
twice daily. Protocols will be institution specific. 
During an acute presentation, the definition of refractory disease may require an 
escalation in therapy. The median time to achieve a clinical response, with daily 
plasma exchange, is approximately 10-15 days [45].  Patients admitted to an ICU 
setting with neurological and /or cardiac features may require longer plasma 
exchange therapy [46].  Patients failing to achieve remission or whose platelet count 
and LDH initially improve but worsen despite on-going treatment would also be 
considered to have refractory disease.   
Relapsing TTP: 
There are a number of identified risk factors that may be associated with or 
precipitate a relapse of iTTP,  
• ADAMTS-13 deficiency (particularly <10% activity) 
• Persistent severe ADAMTS-13 deficiency in remission 
• Persistent anti-ADAMTS-13 antibodies in remission 
or congenital  disease 
• Pregnancy  
• Infection/live vaccinations  
• Drugs including drugs of abuse eg. cocaine, alcohol  
 
In iTTP, a severely reduced ADAMTS-13 activity persisting during remission is 
associated with relapse, particularly when associated with inhibitory autoantibodies 
[47]. Therapy should be considered to clear antibodies and normalize ADAMTS-13 
activity, in patients felt to be at high risk for relapse [16, 18]. Pregnancy [48] , 
infections and live vaccinations in particular may precipitate an acute episode of 
cTTP. Often, an initial acute TTP episode, even though occurring only in adulthood, 
is followed by recurrent episodes [49]. 
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 Factors relating to severity/prognosis of TTP 
• Presence of Anti-ADAMTS-13 IgG antibody associated with severe 
ADAMTS-13 deficiency 
• Raised troponin at presentation 
• Presence of neurological features 
• Older age 
• Low ADAMTS-13 antigen at presentation 
There are few predictors of disease severity, but necessity of intubation and 
ventilation, older age, neurological features [50]and cardiac symptoms and/or raised 
troponin,[51] with high inhibitor levels/IgG autoantibodies to ADAMTS-13 are key 
predictors.  Ethnicity and ADAMTS-13 activity <10% are associated with 
exacerbation and relapse respectively. Non Caucasians have increased 
exacerbation and relapse, but reduced mortality.  Inhibitor or anti-ADAMTS-13 IgG 
levels predicting the severity of disease have not been defined [52], but levels (anti-
ADAMTS-13 IgG >50% or > 2 BU/ml) are associated with a poorer outcome [51]. 
Low ADAMTS-13 antigen level at presentation may be associated with worse clinical 
outcome in iTTP [53]. Routine laboratory parameters such as platelet count, LDH, 
and hemoglobin are not predictive of severity, although failure to improve with 
therapy and hence refractory disease is associated with a worse outcome.  
ADAMTS-13 assays: 
ADAMTS-13 activity: determines the amount of functional ADAMTS-13 via direct or 
indirect measurement of VWF cleavage. Current methods include FRETS-VWF73, 
chromogenic VWF-73 [54], chromogenic VWF-73 [55], FRETS-rVWF71 [56] FRET-
VWF86 and SELDI-TOF mass spectrometry [57]. A standard curve using pooled 
normal plasma (PNP) for each assay plus control samples (e.g. plasma of a cTTP 
patient for an   low range sample; the WHO 1st International Standard ADAMTS-13 
[58]), which have undergone in-house calibration.  
ADAMTS-13 antigen: determines the amount of ADAMTS-13 protein in plasma. Low 
levels appear to be associated with poor prognosis [53]. 
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Anti-ADAMTS-13 antibodies: usually IgG but IgM and IgA may be also relevant. Anti-
ADAMTS-13 antibodies are measured by ELISA, Western blot or 
immunoprecipitation. ADAMTS-13 antibodies by ELISA may be seen in 5%-10% of 
healthy individuals however, this may be manufacturer/assay dependent [59]. ELISA 
or Western blotting using recombinant ADAMTS-13 to detect anti-ADAMTS-13 in 
patient’s plasma can assess the presence of anti-ADAMTS-13 antibodies. In-house 
or commercially available assays should have appropriate validation and controls to 
include low, medium and high antibody titres.  
 
ADAMTS-13 inhibitor assays: identifies and quantitates anti-ADAMTS-13 antibodies 
that functionally inhibit ADAMTS-13 in vitro. Functional ADAMTS-13 inhibitors are 
assessed in classical Bethesda-like mixing studies. Samples are heat-inactivated for 
30 minutes at 56°C to abolish endogenous ADAMTS-13, before mixing, at various 
dilutions,  with PNP.  After incubation at 37°C for 2 hours, residual ADAMTS-13 
activity is measured and the residual activity transformed in Bethesda units,(1BU/ml 
of inhibitor inhibits 50% of normal plasma ADAMTS-13).  For routine purposes it is 
usually sufficient to titrate up to 2 Bethesda units/ml.   
 
Factors affecting ADAMTS-13 levels 
Severe hemolysis with marked hyperbilirubinemia [60]or severe lipemia may give 
falsely low ADAMTS-13 activity results, particularly when using fluorogenic detection 
e.g. FRETS [54]; Free hemoglobin in plasma from intravascular hemolysis can also 
inhibit ADAMTS-13 activity [61]. 
There is good concordance between assays in the range of severe deficiency of 
ADAMTS-13 (defined as either <5% or <10%).  However assay conditions can affect 
results. There are numerous variables in quantification of ADAMTS-13 activity levels 
among different platforms or when performed in different laboratories. Further 
studies involving large series of plasma samples are needed to evaluate the newly 
developed commercial kits. 
Pre-analytic aspects: specimen type and acceptability criteria  
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 ADAMTS-13 activity can be assessed in citrated plasma, serum or lithium-heparin 
plasma. While extensive comparisons between these are missing, small series 
demonstrate equality [62].  EDTA plasma is not suitable for ADAMTS-13 activity 
testing, as it is an irreversible inhibitor of ADAMTS-13 activity.  
Evaluation of assays 
- Detection (sensitivity) limit of the method:  
. For ADAMTS-13 activity measurement (defined as the lowest  activity that is 
distinguishable from buffer or heat inactivated plasma respectively): this should 
be < 5%, but preferably < 1%.  
. For the detection of inhibitors:  difficult to standardize, but a negative control and 
at least 2 positive antibody controls, which have demonstrated reproducibility with 
the technique, should be considered. The detection limit is approximately 0.4-0.6 
BU/ml. 
- Precision of the method: intra-assay reproducibility (within series), inter-assay 
reproducibility (between run in one given laboratory and also inter-laboratory 
precision): should have CVs of  <10%. 
In conclusion, we have developed definitions for TTP and associated TMAs that we 
hope will promote uniformity in publications, associated studies and clinical trials. 
The field is ever expanding and the group will be required to undertake a review 
again in future years.  
 
Acknowledgements 
The development of this document involved key international, primarily clinical, 
experts involved with TTP, HUS and related disorders. The concept was supported 
by the EHA-SWG platelet group, chaired by the late Dr Roberto Stasi (Rome, Italy 
and London, UK). Thanks to Professor HM Tsai, Taiwan, for his valuable contribution 
and review of the manuscript. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Addendum 
M. Scully was responsible for the concept and design. 
M Scully , S Cataland , P Coppo , J de la Rubia , K Friedman,  D Gale, Y Fujimura, J 
Kremer Hovinga, B Lämmle, M Matsumoto, V McDonald, K Pavenshi, F Peyvandi, E 
Sadler,  R Sarode, I Scharrer, A Veyradier, JP Westwood, H Wu reviewed the 
literature, assisted in critical writing and/or revised the content, and agreed the final 
version to be published.  
The members of the International Working group have all contributed to this work, 
and are listed in the Appendix. 
 
Disclosure of Conflict of Interests 
K. Friedman reports personal fees from Ablynx and Baxalta, outside the submitted 
work.  P. Coppo reports grants, personal fees and non-financial support from Alexion 
Inc.; grants from Roche; and personal fees from Ablynx, during the conduct of the 
study. K. Pavenski reports honoraria from Alexion Inc., outside the submitted work. 
B. Lämmle reports grants from Baxter Biosciences and personal fees from Baxalta, 
Alexion Inc., Siemens, and Baxalta, outside the submitted work.  In addition, B. 
Lämmle has a patent von Willebrand factor protease issued. J. Kremer Hovinga 
reports grants, personal fees and non-financial support from Baxalta; personal fees 
from Alexion; and she sat on advisory boards for Ablynx, during the conduct of the 
study. E. Sadler reports personal fees from Ablybx, 23andMe, XO1 Limited, Baxter 
HealthCare, and BioMarin, outside the submitted work.  In addition, E. Sadler has a 
patent Fluorogenic substrate for ADAMTS13, US 8,663,912 issued to Washington 
University. M. Scully reports grants from Baxter Global and personal fees from 
Novartis, Ablynx, and Alexion, outside the submitted work. M. Matsumoto reports 
grants from the Ministry of Health, Labour, and Welfare of Japan and the Ministry of 
Education, Culture, Sports, Science and Technology of Japan, during the conduct of 
the study.  In addition, M. Matsumoto has a patent ADAMTS13 activity assay with 
royalties paid. In addition to having been a member of a scientific advisory board for 
Ablynx, F. Peyvandi reports grants from Alexion, Ablynx, and Biokit; grants and 
personal fees from Biotest, Bayer, Kedrion Biopharma, and Novo Nordisk; and 
personal fees from Octapharma, Sobi, CSL Behring, LFB, and Grifols outside the 
submitted work. Y. Fujimura has a patent ADAMTS13 activity assay from Alfresa 
pending. D. Gale reports personal fees from Alexion, outside the submitted work 
Appendix 
International Working Group for Thrombotic Thrombocytopenic Purpura  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
D. Gale, London, UK; Y. Fujimura, Nara, Japan; V. McDonald, London, UK; F. 
Peyvandi, Milan, Italy; I. Scharrer, Mainz, Germany; A. Veyradier, Paris, France; J. 
P. Westwood, London, UK.  
 
References 
1 Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, 
Szczepiorkowski ZM, Winters JL. Thrombotic thrombocytopenic purpura: 2012 
American Society for Apheresis (ASFA) consensus conference on classification, 
diagnosis, management, and future research. J Clin Apher. 2014; 29: 148-67. 
10.1002/jca.21302. 
2 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. 
Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing 
thrombotic thrombocytopenic purpura. Blood. 1997; 89: 3097-103. 
3 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in 
acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-94. 
10.1056/nejm199811263392203. 
4 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb 
Hemost. 2013; 39: 559-66. 10.1055/s-0033-1343894. 
5 Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Jozsi M. 
Autoimmune forms of thrombotic microangiopathy and membranoproliferative 
glomerulonephritis: Indications for a disease spectrum and common pathogenic 
principles. Mol Immunol. 2009; 46: 2801-7. 10.1016/j.molimm.2009.05.018. 
6 Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH. 
The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res 
Ther. 2013; 15: R12. 10.1186/ar4142. 
7 Keeler E, Fioravanti G, Samuel B, Longo S. Scleroderma renal crisis or 
thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med. 
2015; 46: e39-44. 10.1309/lm72am5xfhzyoqcb. 
8 Turner RC, Chaplinski TJ, Adams HG. Rocky Mountain spotted fever 
presenting as thrombotic thrombocytopenic purpura. Am J Med. 1986; 81: 153-7. 
9 Morton JM, George JN. Microangiopathic Hemolytic Anemia and 
Thrombocytopenia in Patients With Cancer. J Oncol Pract. 2016; 12: 523-30. 
10.1200/jop.2016.012096. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
10 Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, 
Machin SJ, British Committee for Standards in H. Guidelines on the diagnosis and 
management of thrombotic thrombocytopenic purpura and other thrombotic 
microangiopathies. Br J Haematol. 2012; 158: 323-35. 10.1111/j.1365-
2141.2012.09167.x. 
11 Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, 
Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, 
Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B, Reseau 
d'Etude des Microangiopathies Thrombotiques de lA. Prognostic value of inhibitory 
anti-ADAMTS-13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. 
Br J Haematol. 2006; 132: 66-74. 10.1111/j.1365-2141.2005.05837.x. 
12 Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D. Thrombotic 
thrombocytopenic purpura associated with von Willebrand factor-cleaving protease 
(ADAMTS-13) deficiency in children. Semin Thromb Hemost. 2006; 32: 90-7. 
10.1055/s-2006-939764. 
13 Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, 
Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C. Severe deficiency of the 
specific von Willebrand factor-cleaving protease (ADAMTS-13) activity in a subgroup 
of children with atypical hemolytic uremic syndrome. J Pediatr. 2003; 142: 310-7. 
14 Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, Wu HM. Diagnostic and 
prognostic values of ADAMTS-13 activity measured during daily plasma exchange 
therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion 
(Paris). 2014. 10.1111/trf.12762. 
15 Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. 
Relationship between ADAMTS-13 activity in clinical remission and the risk of TTP 
relapse. Br J Haematol. 2008; 141: 651-8. 10.1111/j.1365-2141.2008.07107.x. 
16 Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. 
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration 
during acute episodes and use of prophylaxis to prevent relapse. J Thromb 
Haemost. 2013; 11: 481-90. 10.1111/jth.12114. 
17 Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, 
Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic 
purpura following rituximab is associated with a reduction in IgG antibodies to 
ADAMTS-13. Br J Haematol. 2007; 136: 451-61. 10.1111/j.1365-2141.2006.06448.x. 
18 Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, 
Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, 
Hamidou M, Vernant JP, Veyradier A, Coppo P. Preemptive rituximab infusions after 
remission efficiently prevent relapses in acquired thrombotic thrombocytopenic 
purpura. Blood. 2014; 124: 204-10. 10.1182/blood-2014-01-550244. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
19 Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS-13 mutations 
and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 
2010; 31: 11-9. 10.1002/humu.21143. 
20 Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai 
H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common 
polymorphisms in ADAMTS-13 gene responsible for von Willebrand factor-cleaving 
protease activity. Proc Natl Acad Sci U S A. 2002; 99: 11902-7. 
10.1073/pnas.172277399. 
21 Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang 
AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, 
Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, Tsai HM. 
Mutations in a member of the ADAMTS gene family cause thrombotic 
thrombocytopenic purpura. Nature. 2001; 413: 488-94. 10.1038/35097008. 
22 Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata 
M, Miyata T. Natural history of Upshaw-Schulman syndrome based on ADAMTS-13 
gene analysis in Japan. J Thromb Haemost. 2011; 9 Suppl 1: 283-301. 
10.1111/j.1538-7836.2011.04341.x. 
23 Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful 
management of pregnancy in women with a history of thrombotic thrombocytopaenic 
purpura. Blood Coagul Fibrinolysis. 2006; 17: 459-63. 
10.1097/01.mbc.0000240918.65306.20. 
24 Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, 
Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A. Unexpected 
frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic 
thrombocytopenic purpura. Blood. 2012; 119: 5888-97. 10.1182/blood-2012-02-
408914. 
25 von Krogh AS, Kremer Hovinga JA, Tjonnfjord GE, Ringen IM, Lammle B, 
Waage A, Quist-Paulsen P. The impact of congenital thrombotic thrombocytopenic 
purpura on pregnancy complications. Thromb Haemost. 2014; 111: 1180-3. 
10.1160/th13-08-0713. 
26 Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life 
of von Willebrand factor-cleaving protease after plasma therapy in patients with 
thrombotic thrombocytopenic purpura. Thromb Haemost. 1999; 81: 8-13. 
27 Scully M, Brown J, Patel R, McDonald V, Brown CJ, Machin S. Human 
leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: 
evidence for an immunogenetic link. J Thromb Haemost. 2010; 8: 257-62. 
10.1111/j.1538-7836.2009.03692.x. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
28 Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, Hunt B, Benjamin S, 
Patel R, Machin S, Scully M. Human immunodeficiency virus associated thrombotic 
thrombocytopenic purpura--favourable outcome with plasma exchange and prompt 
initiation of highly active antiretroviral therapy. Br J Haematol. 2011; 153: 515-9. 
10.1111/j.1365-2141.2011.08636.x. 
29 McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic 
thrombocytopenic purpura and simvastatin. Lancet. 1998; 352: 1284-5. 
10.1016/s0140-6736(05)70492-x. 
30 Thomas MR, McDonald V, Machin SJ, Scully MA. Thrombotic 
thrombocytopenic purpura associated with statin therapy. Blood Coagul Fibrinolysis. 
2011; 22: 762-3. 10.1097/MBC.0b013e32834a6170. 
31 Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic 
purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J 
Hematol. 2007; 82: 679-81. 10.1002/ajh.20887. 
32 Sallee M, Cretel E, Jean R, Chiche L, Bourliere M, Poullin P, Lefevre P, 
Durand JM. Thrombotic thrombocytopenic purpura complicating interferon therapy in 
chronic C hepatitis. Gastroenterol Clin Biol. 2008; 32: 145-6. 
33 Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, 
Baudel JL, Provot F, Pene F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, 
Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Chauveau D, Veyradier 
A, Halimi JM, Hamidou M, Coppo P. Risk Factors for Autoimmune Diseases 
Development After Thrombotic Thrombocytopenic Purpura. Medicine (Baltimore). 
2015; 94: e1598. 10.1097/md.0000000000001598. 
34 Schattner A, Friedman J, Klepfish A. Thrombotic thrombocytopenic purpura 
as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol. 2002; 21: 
57-9. 
35 Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, 
Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwege V, 
Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P. Human immunodeficiency 
virus-associated thrombotic microangiopathies: clinical characteristics and outcome 
according to ADAMTS-13 activity. Scand J Immunol. 2008; 68: 337-44. 
10.1111/j.1365-3083.2008.02143.x. 
36 Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer 
JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, 
Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmuller F, Haller H, Herget-
Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, 
Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer 
TN, Michael C, Munte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, 
Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, 
Sayk F, Schmidt BM, Schnatter S, Schocklmann H, Schreiber S, von Seydewitz CU, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, 
Wellhoner P, Wiesner M, Zeissig S, Buning J, Schiffer M, Kuehbacher T. Validation 
of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced 
haemolytic uraemic syndrome: case-control study. BMJ. 2012; 345: e4565. 
10.1136/bmj.e4565. 
37 Vieira-Martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-
Bacchi V. Defining the genetics of thrombotic microangiopathies. Transfus Apher 
Sci. 2016; 54: 212-9. 10.1016/j.transci.2016.04.011. 
38 Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. 
Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of 
literature of the autoimmune form of HUS. Semin Thromb Hemost. 2010; 36: 633-40. 
10.1055/s-0030-1262885. 
39 Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec 
M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg 
G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, 
Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa 
J, Loirat C, Lifton RP. Recessive mutations in DGKE cause atypical hemolytic-
uremic syndrome. Nat Genet. 2013; 45: 531-6. 10.1038/ng.2590. 
40 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, 
Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, 
Remuzzi G, Noris M. Combined complement gene mutations in atypical hemolytic 
uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013; 24: 475-86. 
10.1681/asn.2012090884. 
41 Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, 
Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, 
Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat 
C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-
Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat 
C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. 
N Engl J Med. 2013; 368: 2169-81. 10.1056/NEJMoa1208981. 
42 Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji 
H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima 
T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, 
Kinoshita T, Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N 
Engl J Med. 2014; 370: 632-9. 10.1056/NEJMoa1311084. 
43 Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, 
Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB. Guideline for 
the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. 
Pediatr Nephrol. 2009; 24: 687-96. 10.1007/s00467-008-0964-1. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
44 Miyakawa Y, Imada K, Ichinohe T, Nishio K, Abe T, Murata M, Ueda Y, 
Fujimura Y, Matsumoto M, Okamoto S. Efficacy and safety of rituximab in Japanese 
patients with acquired thrombotic thrombocytopenic purpura refractory to 
conventional therapy. Int J Hematol. 2016; 104: 228-35. 10.1007/s12185-016-2019-
x. 
45 Toussaint-Hacquard M, Coppo P, Soudant M, Chevreux L, Mathieu-Nafissi S, 
Lecompte T, Gross S, Guillemin F, Schneider T. Type of plasma preparation used 
for plasma exchange and clinical outcome of adult patients with acquired idiopathic 
thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort 
study. Transfusion (Paris). 2015; 55: 2445-51. 10.1111/trf.13229. 
46 Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. 
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in 
acute acquired thrombotic thrombocytopenic purpura. Blood. 2011; 118: 1746-53. 
10.1182/blood-2011-03-341131. 
47 Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, 
Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida 
G, Laurenti L, Mannucci PM. ADAMTS-13 and anti-ADAMTS-13 antibodies as 
markers for recurrence of acquired thrombotic thrombocytopenic purpura during 
remission. Haematologica. 2008; 93: 232-9. 10.3324/haematol.11739. 
48 Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, 
Clark A, Creagh D, Rayment R, McDonald V, Roy A, Evans G, McGuckin S, Ni Ainle 
F, Maclean R, Lester W, Nash M, Scott R, P OB. Thrombotic thrombocytopenic 
purpura and pregnancy: presentation, management, and subsequent pregnancy 
outcomes. Blood. 2014; 124: 211-9. 10.1182/blood-2014-02-553131. 
49 Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic 
thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von 
Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001; 14: 437-
54. 10.1053/beha.2001.0142. 
50 Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel 
A, Presne C, Choukroun G, Poullin P, Provot F, Gruson D, Hamidou M, Bordessoule 
D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau 
E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, 
Azoulay E, Rottensteiner H, Veyradier A, Coppo P. Development and validation of a 
predictive model for death in acquired severe ADAMTS-13 deficiency-associated 
idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center 
experience. Haematologica. 2012; 97: 1181-6. 10.3324/haematol.2011.049676. 
51 Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M. 
Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with 
troponin T and IgG antibodies to ADAMTS-13. J Thromb Haemost. 2009; 7: 529-36. 
10.1111/j.1538-7836.2009.03285.x. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
52 Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM. 
Demographic and ADAMTS-13 biomarker data as predictors of early recurrences of 
idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol. 2009; 83: 559-64. 
10.1111/j.1600-0609.2009.01331.x. 
53 Thomas MR, de Groot R, Scully MA, Crawley JT. Pathogenicity of Anti-
ADAMTS-13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. 
EBioMedicine. 2015; 2: 940-50. 10.1016/j.ebiom.2015.06.007. 
54 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first 
fluorogenic substrate for ADAMTS-13 assay. Br J Haematol. 2005; 129: 93-100. 
10.1111/j.1365-2141.2005.05420.x. 
55 Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel 
monoclonal antibody-based enzyme immunoassay for determining plasma levels of 
ADAMTS-13 activity. Transfusion (Paris). 2006; 46: 1444-52. 10.1111/j.1537-
2995.2006.00914.x. 
56 Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, 
Friedman KD, Sadler JE. An optimized fluorogenic ADAMTS-13 assay with 
increased sensitivity for the investigation of patients with thrombotic 
thrombocytopenic purpura. J Thromb Haemost. 2013; 11: 1511-8. 
10.1111/jth.12319. 
57 Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of 
thrombotic thrombocytopenic purpura using surface enhanced laser 
desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb 
Haemost. 2006; 4: 333-8. 10.1111/j.1538-7836.2006.01758.x. 
58 Hubbard AR, Heath AB, Kremer Hovinga JA. Establishment of the WHO 1st 
International Standard ADAMTS-13, plasma (12/252): communication from the SSC 
of the ISTH. J Thromb Haemost. 2015; 13: 1151-3. 10.1111/jth.12881. 
59 Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 
assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010; 8: 631-
40. 10.1111/j.1538-7836.2010.03761.x. 
60 Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia 
interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: 
diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J 
Thromb Haemost. 2007; 5: 866-7. 10.1111/j.1538-7836.2007.02438.x. 
61 Lu RN, Yang S, Wu HM, Zheng XL. Unconjugated bilirubin inhibits proteolytic 
cleavage of von Willebrand factor by ADAMTS-13 protease. J Thromb Haemost. 
2015; 13: 1064-72. 10.1111/jth.12901. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
62 Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F. 
Discrepancies between ADAMTS-13 activity assays in patients with thrombotic 
microangiopathies. Thromb Haemost. 2013; 109: 488-96. 10.1160/th12-08-0565. 
63 Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L. Update on Streptococcus 
pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013; 25: 
203-8. 10.1097/MOP.0b013e32835d7f2c. 
64 Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic 
syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol. 2007; 
22: 2097-103. 10.1007/s00467-007-0604-1. 
65 Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, 
Iacobelli M, Kentouche K, Lammle B, Moake JL, Richardson P, Socie G, Zeigler Z, 
Niederwieser D, Barbui T. Diagnostic criteria for hematopoietic stem cell transplant-
associated microangiopathy: results of a consensus process by an International 
Working Group. Haematologica. 2007; 92: 95-100. 
66 Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, 
Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children 
with severe hematopoietic stem cell transplantation-associated thrombotic 
microangiopathy. Biol Blood Marrow Transplant. 2014; 20: 518-25. 
10.1016/j.bbmt.2013.12.565. 
67 Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and 
management of disseminated intravascular coagulation. British Committee for 
Standards in Haematology. Br J Haematol. 2009; 145: 24-33. 10.1111/j.1365-
2141.2009.07600.x. 
68 Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, 
Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations 
in complement regulatory proteins predispose to preeclampsia: a genetic analysis of 
the PROMISSE cohort. PLoS Med. 2011; 8: e1001013. 
10.1371/journal.pmed.1001013. 
69 Martin JN, Jr., Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. 
The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, 
elevated liver enzyme levels, and low platelet count) syndrome classification. Am J 
Obstet Gynecol. 1999; 180: 1373-84. 
70 Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, 
Yarnold PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Luu TH, Richey EA, Fisher 
MJ, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y, Bennett CL. 
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): 
review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-
2008). Kidney Int Suppl. 2009: S20-4. 10.1038/ki.2008.613. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
71 Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic 
thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, 
and long-term outcomes. Ann Intern Med. 2001; 135: 1047-51. 
72 Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, 
Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, 
Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N 
Engl J Med. 2008; 358: 1129-36. 10.1056/NEJMoa0707330. 
73 McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. 
Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of 
seven cases from a regional UK TTP registry. Br J Haematol. 2009; 144: 430-3. 
10.1111/j.1365-2141.2008.07458.x. 
74 Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lammle B, Kremer 
Hovinga JA, George JN. Pancreatitis preceding acute episodes of thrombotic 
thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a 
systematic review of published reports. Haematologica. 2007; 92: 936-43. 
75 Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic 
anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 
2012; 91: 195-205. 10.1097/MD.0b013e3182603598. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Disease Summary of Disease Comment 
TTP Acute haematological 
emergency, requiring 
prompt diagnosis and 
treatment. More likely to 
have 
neurological/cardiac 
features-but a multi 
system disorder. 
ADAMTS-13 measured 
for definitive diagnosis. 
Plasma exchange is the 
mainstay of treatment, 
typically additional  
immunomodulating 
therapy required in iTTP. 
HUS 
 
 
A. IA-HUS 
 
 
 
The TMA presents 5-7 
days after the infection 
with haemorrhagic 
colitis. 
 
 
 
 
Confirmation of infection 
is serological and/PCR. 
B  CM-HUS CM-HUS can be 
triggered by infection 
(and diarrhoea maybe 
present at presentation), 
vaccinations, or 
pregnancy. . 
 
Diagnosis may be 
confirmed by 
complement mutations 
eg CFH, CFI, MCP, 
CFB, C3 or anti CFH 
antibodies. Homozygous 
or compound 
heterozygous 
diacylglycerol kinase 
(DGKE) mutations  
typically do not respond 
to current complement 
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inhibitors [39]  Treatment 
decisions must be made 
on the basis of the 
clinical presentation and 
absence of severe 
ADAMTS-13 deficiency. 
A response to anti-
complement therapy 
may provide 
confirmation of the 
diagnosis. 
C. Streptococcus  
pneumoniae 
This is seen almost 
exclusively in young 
children. Typically 
present with pneumonia. 
Incidence reduced since 
polyvalent vaccine (in 
some countries). Have a 
DAT positive haemolytic 
anaemia 
Thomsen-Friedenreich 
cryptoantigen, present 
on red cells, platelet, 
glomeruli and 
hepatocytes are 
exposed by 
neuramindase, produced 
by all subtypes of 
Streptococcus 
pneumoniae. The TF 
antigen interacts with 
IgM antibodies, resulting 
in agglutination. 
Treatment is supportive, 
but still washed blood 
products may be 
requested [63] 
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D. Cobalamin C 
deficiency 
A rare cause of HUS that 
is caused by recessive 
mutations of the 
methylmalonic aciduria 
(cobalamin deficiency) 
cblC type, with 
homocystinuria 
(MMACHC) gene. 
Presentation is typically 
within the first year of life 
[64]. 
 
 
Connective tissue 
disease 
MAHAT may be a 
primary feature. Further 
systemic 
features/laboratory 
testing confirm the 
diagnosis 
Autoimmune screen, 
tissue biopsy eg SLE, 
scleroderma, 
antiphospholipid 
syndrome, vasculitis (eg 
ANCA) 
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Transplantation, either 
solid organ or bone 
marrow/ hematopoietic 
stem cell (HSC): 
May present with 
MAHAT with or without 
renal involvement. It is 
typically associated with 
immunosuppressive 
therapy, such as 
Tacrolimus, Ciclosporin 
A, underlying 
opportunistic infections 
(eg CMV, Adenovirus, 
Aspergillus) or graft-
versus-host disease [65], 
HSC transplant 
associated TMAs do not 
have severe ADAMTS-
13 deficiency (ie <10%). 
Complement alternative 
pathway dysregulation 
may be involved in the 
pathogenesis of HSCT-
TMA . In patients 
developing  TMA post 
renal transplantation, 
consideration should be 
given to possible CM-
HUS, which may have 
been  the cause of the 
initial renal failure and 
the failed  transplanted 
kidney [66] 
 
Disseminated 
intravascular 
Coagulation (DIC) 
DIC is associated with 
abnormalities in routine 
coagulation and CBC 
screens [67]. 
DIC is typically due to an 
underlying precipitant 
such as sepsis, 
malignancy, 
haematological 
disorders, obstetric 
complications or trauma. 
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Pregnancy associated 
TMAS 
Pre-eclampsia and 
HELLP occur in the 
second half of 
pregnancy or early post 
partum.  
Complement activation 
in HELLP or pre-
eclampsia may trigger 
the development of 
TMA. Complement 
abnormalities have been 
identified in some cases 
of HELLP/pre-eclampsia 
[68],  
A. HELLP syndrome There are no specific 
diagnostic clinical or 
laboratory factors. 
ADAMTS-13 activity is 
typically normal. HELLP 
can be divided into type 
1, 2 and 3 based on the 
platelet count (<50 
x109/L, 50-100 x109/L, 
100-150 x109/L) [69].  
 
May be associated with 
complications such as 
DIC, and placental 
abruption. 
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B. Pre-eclampsia Defined as de novo 
hypertension (>140/90 
mm Hg) and proteinuria 
(>0.3 g per 24 hours) 
after 20 weeks of 
gestation . 
Control of BP. Delivery 
will improve the 
situation. 
Drugs Ticlodipine [70] may be 
associated with 
autoantibodies to 
ADAMTS-13, case 
reports with  quinine 
[71], simvastatin, 
trimethoprim or 
interferon. Clopidogrel is 
not associated with TTP. 
TMA may occur with 
gemcitabine, bleomycin, 
and mitomycin. VEGF 
inhibitors were 
associated with features 
of TMA reminiscent of 
HUS [72]. 
Stopping the offending 
drug maybe associated 
with improvement.  
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Table 1: Summary of characteristics associated with conditions presenting 
with microangiopathic haemolytic anaemia and thrombocytopenia (MAHAT) 
IR-HUS: Infection related haemolytic uraemic syndrome; PEX: plasma exchange, 
BP: blood pressure, HELLP: haemolysis, elevated liver enzymes & low platelets, 
DIC: disseminated intravascular coagulation,  TMA: thrombotic microangiopathy, 
CM-HUS: . Complement mediated-HUS 
 
Pancreatitis Caused by alcohol 
excess, bile duct 
obstruction or possibly 
an autoimmune 
precipitant [73].  
ADAMTS-13 levels may 
not be severely reduced 
[74]. Identifying  the 
underlying condition 
reduces the risk of 
further relapses.  
 
Malignancy In patients with MAHAT 
for whom a severe 
deficiency of ADAMTS-
13 activity is not 
confirmed, tumour 
markers and radiological 
investigations should be 
considered [75].  
 
ADAMTS-13 activity is 
normal or mildly 
decreased. 
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Figure 1: Differential diagnos
with MAHA 
Key: MAHA: microangiopathic h
thrombocytopenia TTP: thrombo
associated HUS, PCR: polymer
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